no analyst mention one way or the other, no comment from Pucci in the press release...not even a "this is interesting" whatever, no indication of what now...kinda bizarre. .70 HR did not knock the ball out of the park but if met + had been the sole focus of the study, we'd probably be looking at an NDA and we'd have $10+ stock. Next possible catalyst results from ATTENTION?? Question: if met biomarker used in advance (as in HCC study), would that be likely to improve the result or impossible to know at this point?? of course, other catalyst (up or down) is HCC being able to proceed or not.